Original articleSafety of Clopidogrel in Hip Fracture Surgery
Section snippets
Overview and Study Design
This study was a population-based, retrospective cohort study with a 2:1 matched comparison cohort using the database of the Rochester Epidemiology Project (REP). Epidemiological research in Olmsted County, Minnesota, is possible because the county is geographically isolated from other urban centers, and nearly all medical care is delivered to the population by a limited number of local health care providers. Providers of health care to the community have agreed to share their medical records
Results
Our search of the REP identified 2061 patients hospitalized for hip fracture during the study period, 40 (2%) of whom were identified as taking clopidogrel and made up the clopidogrel cohort. The control group comprised 80 patients matched 2:1 from among the remaining 2021 patients with hip fracture. Baseline characteristics are summarized in Table 1. Median age at hip fracture surgery was 83 years for the clopidogrel group and 84 years in the control group. The percentage of men was 45% in
Discussion
This observational study supports our hypothesis that there is no difference in perioperative bleeding complications or mortality in patients who undergo prompt operative treatment of hip fracture while taking clopidogrel compared with patients not taking clopidogrel.
Our clopidogrel cohort and control cohort were similar. There was no significant operative delay in either cohort: on average, both groups had surgical intervention within 36 hours of admission. This is important because most prior
Conclusion
We conducted an observational, population-based, retrospective cohort study to test the hypothesis that there is no increase in postoperative bleeding complications or mortality in patients who undergo prompt operative treatment of hip fracture while taking clopidogrel. Although the small sample size in our study precludes making a definitive conclusion, we found no evidence that prompt surgical treatment of hip fracture in patients taking clopidogrel compromises perioperative outcomes.
Acknowledgments
We thank Donna K. Lawson, LPN, and Kathleen E. Wolfert, RN, BSN, for their help in data collection and management. Data were analyzed by Christine M. Lohse, MS.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the study sponsors.
References (18)
- et al.
Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures
Br J Anaesth
(2011) - et al.
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction
Br J Anaesth
(2007) - et al.
Perioperative management of trauma patients admitted on clopidogrel (Plavix): a survey of orthopaedic departments across the United Kingdom
Injury
(2007) - et al.
Is clopidogrel stopped prior to hip fracture surgery—a survey of current practice in the United Kingdom
Injury
(2007) - et al.
Clopidogrel therapy—implications for hip fracture surgery
Injury
(2008) - et al.
Femoral neck fractures in patients on Clopidogrel: the effect of delaying surgery and the introduction of the new SIGN guidelines
Surgeon
(2011) History of the Rochester Epidemiology Project
Mayo Clin Proc
(1996)- et al.
Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery
J Vasc Surg
(2011) - et al.
Preoperative thienopyridine use and outcomes after surgery: a systematic review
Am J Med
(2012)
Cited by (27)
Minimally invasive acute care surgery
2022, Current Problems in SurgeryDeep Vein Thrombosis and Pulmonary Embolism Considerations in Orthopedic Surgery
2017, Orthopedic Clinics of North AmericaDiscontinuation of Plavix<sup>®</sup> (clopidogrel) for hip fracture surgery. A systematic review of the literature
2016, Revue de Chirurgie Orthopedique et TraumatologiqueDiscontinuation of Plavix<sup>®</sup> (clopidogrel) for hip fracture surgery. A systematic review of the literature
2016, Orthopaedics and Traumatology: Surgery and ResearchEvaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations
2016, Journal of Foot and Ankle SurgeryCitation Excerpt :Some examples can be seen in other realms of surgery, including orthopedic hip surgery. A retrospective cohort study found no difference in perioperative bleeding complications or mortality in patients undergoing hip fracture surgery between patients with perioperative clopidogrel therapy and those without (18). An analysis of 102 patients undergoing hemiarthoplasty showed no statistically significant difference in multiple bleeding outcomes, including pre- and postoperative hemoglobin levels and transfusion rates between groups receiving clopidogrel preoperatively and those not receiving clopidogrel (26).
Grant Support: This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigators: Walter A. Rocca, MD, MPH, and Barbara P. Yawn, MD, MSc, and grant number R01-AR30582 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). The study was funded by an internal grant from the Mayo Clinic Division of General Internal Medicine and a Write-up and Publish (WRAP) grant from the Mayo Clinic Department of Medicine.
Potential Competing Interests: Dr Mabry has a pending contract with Zimmer to provide consultation regarding a new total knee prosthesis. Dr Sems receives royalties from DePuy Orthopaedics, Inc, for a hip implant he designed.